Loading...
Market
What will be the change in Phathom Pharmaceuticals' stock price by December 31, 2024?
2
Resolution / Starting Odds
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Decrease by less than 20% • 25%
Decrease by 20% or more • 25%
NYSE or NASDAQ stock price data
Story
Phathom Pharmaceuticals Receives FDA Approval for VOQUEZNA for GERD Heartburn Relief in Adults
Jul 18, 2024, 12:04 PM
Phathom Pharmaceuticals has received FDA approval for its drug VOQUEZNA (vonoprazan) tablets. The medication is intended for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. This approval, announced on July 17 and July 18, marks a significant milestone for Phathom Pharmaceuticals, which has a short interest of over 40%. VOQUEZNA is a potassium-competitive acid blocker (PCAB), expanding its approval to cover more GERD patients.
View original story
Similar markets
Below $150 • 25%
$150 - $175 • 25%
$175 - $200 • 25%
Above $200 • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease • 25%
No significant change • 25%
Increase by more than 5% • 25%
Increase by up to 5% • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Below $60 • 25%
$60-$70 • 25%
$70-$80 • 25%
Above $80 • 25%
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Outperform by more than 5% • 25%
Perform within 5% of S&P 500 • 25%
Underperform by 1-5% • 25%
Underperform by more than 5% • 25%
Above $10 • 25%
$8 to $10 • 25%
$6 to $8 • 25%
Below $6 • 25%
Market cap increases by over 10% • 25%
Market cap increases by 0-10% • 25%
Market cap decreases by 0-10% • 25%
Market cap decreases by over 10% • 25%